A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study

Cancer Patients ◽

Phase Ii ◽

Liquid Biopsy ◽

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype

British Journal of Cancer ◽

10.1038/s41416-018-0348-7 ◽

2018 ◽

Vol 120 (2) ◽

pp. 190-195 ◽

Cited By ~ 9

Author(s):

David Páez ◽

María Tobeña ◽

Julen Fernández-Plana ◽

Ana Sebio ◽

Anna C. Virgili ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

High Dose ◽

Efficacy And Safety ◽

Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients

Scientific Reports ◽

10.1038/s41598-020-60212-1 ◽

2020 ◽

Vol 10 (1) ◽

Cited By ~ 7

Author(s):

Diego de Miguel Pérez ◽

Alba Rodriguez Martínez ◽

Alba Ortigosa Palomo ◽

Mayte Delgado Ureña ◽

Jose Luis Garcia Puche ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Liquid Biopsy ◽

Extracellular Vesicle ◽

Disease Identification ◽

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial

Annals of Oncology ◽

10.1093/annonc/mdz082 ◽

2019 ◽

Vol 30 (5) ◽

pp. 796-803 ◽

Cited By ~ 5

Author(s):

C. Santos ◽

D. Azuara ◽

J.M. Viéitez ◽

D. Páez ◽

E. Falcó ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

High Sensitivity ◽

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial

Annals of Oncology ◽

10.1093/annonc/mdz155.088 ◽

2019 ◽

Vol 30 ◽

pp. iv23-iv24 ◽

Cited By ~ 3

Author(s):

A. Fernández Montes ◽

N. Martinez Lago ◽

J. De la Cámara Gómez ◽

M. Covela Rúa ◽

A. Cousillas Castiñeiras ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Treatment Phase ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

First Line ◽

397O Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.508 ◽

2020 ◽

Vol 31 ◽

pp. S409-S410

Author(s):

E. Martinelli ◽

G. Martini ◽

T. Troiani ◽

F. Pietrantonio ◽

A. Avallone ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Wild Type ◽

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

British Journal of Cancer ◽

10.1038/sj.bjc.6603493 ◽

2007 ◽

Vol 96 (3) ◽

pp. 439-444 ◽

Cited By ~ 21

Author(s):

E Bajetta ◽

◽

M Di Bartolomeo ◽

R Buzzoni ◽

L Mariani ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Colorectal Cancer Patients ◽

First Line Treatment

A Phase II Study of Panitumumab Plus Irinotecan for Metastatic Colorectal Cancer Patients with Wild KRAS Exon 2, Resistant to Fluoropyrimidine, Oxaliplatin and Irinotecan in Japanese. (OGSG1001)

Annals of Oncology ◽

10.1093/annonc/mdu165.235 ◽

2014 ◽

Vol 25 ◽

pp. ii89

Author(s):

Hata Taishi ◽

Yoshida Motoki ◽

Taira Koichi ◽

Sugimoto Naotoshi ◽

Tokunaga Yukihiko ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Exon 2 ◽

Colorectal Cancer Patients ◽

Kras Exon

Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers

Annals of Oncology ◽

10.1093/annonc/mdy151.205 ◽

2018 ◽

Vol 29 ◽

pp. v57 ◽

Cited By ~ 1

Author(s):

G. Bruera ◽

S. Massacese ◽

F. Pepe ◽

U. Malapelle ◽

A. Dal Mas ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Wild Type ◽

First Line ◽

Triplet Chemotherapy ◽

Colorectal Cancer Patients ◽

Preliminary Phase

A Phase II Study of ANGIOZYME® in combination with 5-fluorouracil, leucovorin and ironotecan in the treatment of metastatic colorectal cancer patients

European Journal of Cancer ◽

10.1016/s0959-8049(02)80877-2 ◽

2002 ◽

Vol 38 ◽

pp. S72

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients

BMC Cancer ◽

10.1186/1471-2407-14-986 ◽

2014 ◽

Vol 14 (1) ◽

Cited By ~ 4

Author(s):

Wenhua Li ◽

Jianming Xu ◽

Lin Shen ◽

Tianshu Liu ◽

Weijian Guo ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽